Karuna Therapeutics

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Karuna Therapeutics is committed to improving the lives of patients with disabling neuropsychiatric conditions by developing novel, mechanism-based therapies.

At Karuna, we strive to bring safe and effective treatments to patients with disabling neuropsychiatric conditions by leveraging our deep understanding of the disease and an extensive network of clinical and academic partners.

Karuna Therapeutics has been awarded numerous grants and awards for its research and development, including the “Innovation in Neuroscience Award” from Stanford Neurosciences Institute and the “Innovation of the Year Award” from San Diego Science Alliance. In addition, the company has received international recognition finishing as a top-three finalist in the 2019 Dr. Antonio Afini Innovation Prize of the World Federation of Neurology.